Dini G, Cancedda R, Locatelli F, Bosi A, Bandini G, Alessandrino E P, Porta F, Uderzo C, Messina C, Fagioli F, Arcese W, Marenco P, Fanin R, Falda M, Soligo D, La Nasa G, Giardini C, Pession A, Scimè R, Di Bartolomeo P, Bruno B, Garbarino L, Lamparelli T, Giorgiani G, Lanino E, Manzitti C, Bacigalupo A
U.O. Ematologia-Oncologia Pediatrica, IRCCS G. Gaslini, Genova, Italy.
Haematologica. 2000 Nov;85(11 Suppl):30-6.
Unrelated donor bone marrow transplant (UD-BMT) has become an attractive alternative source of hematopoietic cells for patients lacking a matched sibling. The aim of this paper was to report on results of the 696 UD BMTs performed in 31 Italian institutions during the first 10 years of activity of the Italian Bone Marrow Donor Registry (IBMDR). In 1989 the Italian Bone Marrow Transplant Group (GITMO) established the IBMDR to facilitate donor search and marrow procurement for patients lacking an HLA identical sibling. By end of December 1999, 260,000 HLA-A, B typed volunteer donors had been cumulatively registered and 2,620 searches had been activated for Italian patients. At least one HLA-A, B, DRB1 matched donor was found for 54% of the patients and 696 UD BMTs were performed. In 50% of cases the donor was found in the IBMDR and in 50% in 15 other Registries. The average time from search activation to transplant was 6 months for disease other than CML. For CML it was 14 months. Actuarial 12-month transplant-related mortality (TRM) was 68% in patients grafted between 1979 and 1992 and 44% for patients grafted after 1993. Twenty-eight per cent of patients developed grade III or IV acute GvHD and 24% developed extensive chronic GvHD. The rate of disease free survival at three years was 57% for patients with 1st chronic phase CML, 37% for patients with 1st or 2nd CR ALL, 31% for AML or MDS patients < or = 18 years of age and 54% for patients with inborn errors. We conclude that the IBMDR has benefited a substantial number of patients lacking a matched sibling and has facilitated the recruitment of UDs into the international donor pool. The long time required for the search is the major obstacle to the success of this programme. This suggests that early transplant and a decrease in TRM could further improve these encouraging results.
无关供体骨髓移植(UD-BMT)已成为缺乏匹配同胞供体患者的一种有吸引力的造血细胞替代来源。本文旨在报告意大利骨髓供体登记处(IBMDR)成立头10年期间,在31家意大利机构进行的696例无关供体骨髓移植的结果。1989年,意大利骨髓移植小组(GITMO)成立了IBMDR,以方便为缺乏HLA相同同胞供体的患者寻找供体和采集骨髓。到1999年12月底,累计登记了260,000名HLA-A、B分型的志愿供体,并为意大利患者启动了2,620次供体搜索。至少为54%的患者找到了至少一名HLA-A、B、DRB1匹配的供体,并进行了696例无关供体骨髓移植。在50%的病例中,供体在IBMDR中找到,50%在其他15个登记处找到。除慢性粒细胞白血病(CML)外的其他疾病,从搜索启动到移植的平均时间为6个月。对于CML,为14个月。1979年至1992年接受移植的患者,12个月的精算移植相关死亡率(TRM)为68%,1993年后接受移植的患者为44%。28%的患者发生III级或IV级急性移植物抗宿主病(GvHD),24%的患者发生广泛慢性GvHD。慢性粒细胞白血病慢性期1患者三年无病生存率为57%,急性淋巴细胞白血病(ALL)首次或第二次完全缓解(CR)患者为37%,18岁及以下急性髓系白血病(AML)或骨髓增生异常综合征(MDS)患者为31%,先天性疾病患者为54%。我们得出结论,IBMDR使大量缺乏匹配同胞供体的患者受益,并促进了无关供体进入国际供体库。搜索所需的长时间是该项目成功的主要障碍。这表明早期移植和降低TRM可能会进一步改善这些令人鼓舞的结果。